Few clinical trials incorporate studies of evolutionary cancer biology, despite the frequent emergence of acquired resistance to anticancer therapies. This problem motivated the first CRUK Marshall Symposium on Cancer Evolution in May 2017, which provided a forum for evolutionary and ecological theorists, cancer biologists, and clinicians to consider how evolutionary biology might inform improvements in cancer medicine. Herein, we discuss the key themes and opportunities for the future.

中文翻译：

---

进化与癌症医学——变革性见解


尽管经常出现抗癌疗法的获得性耐药性，但很少有临床试验纳入癌症进化生物学的研究。这个问题促使 2017 年 5 月召开第一届 CRUK 马歇尔癌症进化研讨会，该研讨会为进化和生态理论家、癌症生物学家和临床医生提供了一个论坛，以思考进化生物学如何为癌症医学的改进提供信息。在此，我们讨论未来的关键主题和机遇。